Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review)
- Authors:
- Irena Pintea
- Carina Petricau
- Dinu Dumitrascu
- Adriana Muntean
- Daniel Constantin Branisteanu
- Daciana Elena Branisteanu
- Diana Deleanu
-
Affiliations: Allergy Department, ‘Professor Doctor Octavian Fodor’ Regional Institute of Gastroenterology and Hepatology, 400000 Cluj‑Napoca, Romania, Anatomy Discipline, ‘Iuliu Hatieganu’ University of Medicine and Pharmacy, 400000 Cluj‑Napoca, Romania, Department of Ophthalmology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania, Department of Dermatology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania - Published online on: July 3, 2021 https://doi.org/10.3892/etm.2021.10381
- Article Number: 949
-
Copyright: © Pintea et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
International drug monitoring. The role of national centers. Report of a WHO meeting. World Health Organ Tech Rep Ser. 498:1–25. 1972.PubMed/NCBI | |
|
Bousquet PJ, Demoly P, Romano A, Aberer W, Bircher A, Blanca M, Brockow K, Pichler W, Torres MJ, Terreehorst I, et al: Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project. Allergy. 64:194–203. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, Khan DA, Lang DM, Park HS, Pichler W, et al: International consensus on drug allergy. Allergy. 69:420–437. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Rawlins MD and Thompson JW: Pathogenesis of adverse drug reactions. In: Textbook of adverse reactions. Davies DM (ed), Oxford University Press, pp44, 1977. | |
|
Thong B and Vervloet D: Drug Allergies. WAO. Available from: https://www.worldallergy.org/education-and-programs/education/allergic-disease-resource-center/professionals/drug-allergies, 2007. | |
|
Hausmann OV, Seitz M, Villiger PM and Pichler WJ: The complex clinical picture of side effects to biologicals. Med Clin North Am. 94:791–804. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Pichler WJ: Adverse side-effects to biological agents. Allergy. 61:912–920. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Sunthralingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner M D and Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 355:1018–1028. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Vasquez EM, Fabrega AJ and Pollak R: OKT3-induced cytokine-release syndrome: Occurrence beyond the second dose and association with rejection severity. Transplant Proc. 27:873–874. 1995.PubMed/NCBI | |
|
Wing M: Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction. J Immunotoxicol. 5:11–15. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Cheifetz A and Mayer L: Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 72:250–256. 2005.PubMed/NCBI | |
|
Shelley WB, Talanin N and Shelley ED: Polysorbate 80 hypersensitivity. Lancet. 345:1312–1313. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Steele RH, Limaye S, Cleland B, Chow J and Suranyi MG: Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology (Carlton). 10:317–320. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Price KS and Hamilton RG: Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 28:313–319. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Jover Cerdá V, Rodríguez Pacheco R, Doménech Witek J, Marco de la Calle FM and de la Sen Fernández ML: Immediate hypersensitivity to polyethylene glycols in unrelated products: When standardization in the nomenclature of the components of drugs, cosmetics, and food becomes necessary. Allergy Asthma Clin Immunol. 15(9)2019.PubMed/NCBI View Article : Google Scholar | |
|
Stone CA Jr, Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, Hemler JA and Phillips EJ: Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 7:1533–1540.e8. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A and Schleypen J: Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther. 32:1597–1609. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE and Castells MC: Hypersensitivity reactions to mAbs: 105 Desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 124:1259–1266. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S and Maggi E: Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 65:657–6561. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Mezzano V, Giavina-Bianchi P, Picard M, Caiado J and Castells M: Drug desensitization in the management of allergy and anaphylaxis to chemotherapeutic agents and monoclonal antibodies. BioDrugs. 28:133–144. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Georgitis JW, Browning MC, Steiner D and Lorentz WB: Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann Allergy. 66:343–347. 1991.PubMed/NCBI | |
|
Proctor L, Renzulli B, Warren S and Brecher ME: Transfusion medicine illustrated. Monoclonal antibody-stimulated serum sickness. Transfusion. 44(955)2004.PubMed/NCBI View Article : Google Scholar | |
|
Krishna M and Nadler SG: Immunogenicity to biotherapeutics-the role of anti-drug immune complexes. Front Immunol. 7(21)2016.PubMed/NCBI View Article : Google Scholar | |
|
Han PD and Cohen RD: Managing immunogenic responses to infliximab: Treatment implications for patients with Crohn's disease. Drugs. 64:1767–1777. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L and Dijkmans L: Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 54:711–715. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A and Rutgeerts P: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 348:601–608. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Haraoui B, Cameron L, Ouellet M and White B: Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol. 33:31–36. 2006.PubMed/NCBI | |
|
Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X and Marcelli C: Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: A real issue, a clinical perspective. Ann Rheum Dis. 72:165–178. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL and Bendtzen K: Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 68:1739–1745. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L and Wolbink GJ: Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 305:1460–1468. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Abdullah SE, Haigentz M Jr and Piperdi B: Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: Pathophysiology and management. Chemother Res Pract. 2012(351210)2012.PubMed/NCBI View Article : Google Scholar | |
|
Rauer S, Stork L, Urbach H, Stathi A, Marx A, Süss P, Prinz M, Brück W and Metz I: Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy. Neurology. 91:e359–e363. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Bouman CA, van Herwaarden N, van den Hoogen FH, Fransen J, van Vollenhoven RF, Bijlsma JW, Maas AV and den Broeder AA: Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-Year data of the DRESS study-a randomised controlled pragmatic non-inferiority strategy trial. Ann Rheum Dis. 76:1716–1722. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Shah KM, Rancour EA, Al-Omari A and Rahnama-Moghadam S: Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome. Dermatol Online J 24: Jun 6, 2018 (Epub ahead of print). | |
|
Salati M, Pifferi M, Baldessari C, Bertolini F, Tomasello C, Cascinu S and Barbieri F: Stevens-Johnson syndrome during nivolumab treatment of NSCLC. Ann Oncol. 29:283–284. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Saw S, Lee HY and Ng QS: Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur J Cancer. 81:237–239. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Demirtas S, El Aridi L, Acquitter M, Fleuret C and Plantin P: Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome. Ann Dermatol Venereol. 144:65–66. 2017.PubMed/NCBI View Article : Google Scholar : (In French). | |
|
Didona D, Paolino G, Garcovich S, Caposiena Caro RD and Didona B: Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab. J Eur Acad Dermatol Venereol. 30:e83–e84. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Fallon MJ and Heck JN: Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy. J Oncol Pharm Pract. 21:388–392. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Wang CY, Khoo C, McCormack CJ, Xu W and Pan Y: Acute localised exanthematous pustulosis secondary to pembrolizumab. Australas J Dermatol. 58:322–323. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Maranduca MA, Branisteanu D, Serban DN, Branisteanu DC, Stoleriu G, Manolache N and Serban IL: Synthesis and physiological implications of melanic pigments. Oncol Lett. 17:4183–4187. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Hwang SJ, Carlos G, Wakade D, Sharma R and Fernandez-Penas P: Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma. Melanoma Res. 26:417–420. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Blendea A, Georgescu CV, Ţolea I, Brănişteanu DE and Costache A: An unusual cutaneous malignant melanoma arised de novo: A case report. Rom J Morphol Embryol. 56:1217–1221. 2015.PubMed/NCBI | |
|
Suga H, Sugaya M, Tamaki Z, Yamamoto M, Tada Y and Sato S: Varicella like generalized pustulosis induced by adalimumab. Int J Dermatol. 52:890–892. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Bosanquet DC, Davies WL, May K, Harding KG and Patel GK: Acute generalised exanthematous pustulosis following intravitreal Ranibizumab. Int Wound J. 8:317–319. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Popa C, Leandro MJ, Cambridge G and Edwards JC: Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford). 46:626–630. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese EC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, et al: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54:2793–2806. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Koo S, Marty FM and Baden LR: Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am. 24:285–306. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, Dougados M, Ferraccioli G, Jaeger U, Klareskog L, et al: Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 66:143–150. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Gelinck LB, Teng YK, Rimmelzwaan GF, van den Bemt BJF, Kroon FP and van Laar JM: Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 66:1402–1403. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Kelsey A, Chirch LM and Payette MJ: Tuberculosis and interleukin blocking monoclonal antibodies: Is there risk? Dermatol Online J. 24(13030/qt58j4n38m)2018.PubMed/NCBI | |
|
Ramos-Casals M, Roberto-Perez-Alvarez Diaz-Lagares C, Cuadrado MJ and Khamashta MA: BIOGEAS Group. Autoimmune diseases induced by biological agents: A double-edged sword? Autoimmun Rev. 9:188–193. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Perez-Alvarez R, Pérez-de-Lis M and Ramos-Casals M: BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 25:56–64. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Grange JD, Duquesne N, Roubeyrol F, Branisteanu D, Sandon K, Fleury J, Gerard JP, Chauvel P, Pinzaru G, Jean-Louis B and Bievelez B: Double irradiation for macroscopic radioresistance or recurrence of melanomas of the posterior uvea: Clinical, ballistic, therapeutic and prognostic aspects: Series of 19 cases among 462 patients. J Fr Ophtalmol. 22:1054–1063. 1999.PubMed/NCBI(In French). | |
|
Brănişteanu DE, Mihaila G, Alupoaei A, Ciubotariu E, Cherciu M and Brănişteanu DE: Options and therapy limits in a case of severe psoriasis. J Eur Acad Dermatol Venereol. 24(40)2010. | |
|
Khobzey K, Liskova I, Szegedi A, Pavlovsky L, Lunder T, Kingo K, Miljković J, Péč J, Bohinc M and Hojnik M: Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice. Acta Dermatovenerol Alp Pannonica Adriat. 26:11–14. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Brănişteanu DE, Voicu CM, Creţu A, Dimitriu A, Luca MC and Sălăvăstru CM: Adverse reactions of biological therapy for psoriasis. Rev Med Chir Soc Med Nat. 119:38–44. 2015.PubMed/NCBI | |
|
Lin JE, Reddy S, Shah VV and Wu JJ: A review of neurologic complications of biologic therapy in plaque psoriasis. Cutis. 101:57–60. 2008.PubMed/NCBI | |
|
Nakamura K, Kawasaki E, Imagawa A, Awata T, Ikegami H, Uchigata Y, Kobayashi T, Shimada A, Nakanishi K, Makino H, et al: Type 1 diabetes and interferon therapy: A nationwide survey in Japan. Diabetes Care. 34:2084–2089. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Zornitzki T, Malnick S, Lysyy L and Knobler H: Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol. 21:233–239. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A and Emery P: Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis. Ann Rheum Dis. 70:1895–1904. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH and Symmons D: Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 20:119–130. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB and Gelfand JM: The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 64:1035–1050. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Thompson AE, Rieder SW and Pope JE: Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials. Arthritis Rheum. 63:1479–1485. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Parakkal D, Sifuentes H, Semer R and Ehrenpreis ED: Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: Expanding the groups at risk. Eur J Gastroenterol Hepatol. 23:1150–1156. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, Dreyer L, Hetland ML, Cordtz R, Hyrich K, et al: Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: A European registries collaborative project. Ann Rheum Dis. 76:2025–2030. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Peréz-Soler R and Saltz L: Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol. 23:5235–5246. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Kwon HJ, Coté TR, Cuffe MS, Kramer JM and Braun MM: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 138:807–811. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Khasnis AA and Calabrese LH: Tumor necrosis factor inhibitors and lung disease: A paradox of efficacy and risk. Semin Arthritis Rheum. 40:147–163. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Dixon WG, Hyrich KL, Watson KD and Lunt M: BSRBR Control Centre Consortium and Symmons DP; British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: Results from the British society for rheumatology biologics register. Ann Rheum Dis. 69:1086–1091. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Collamer AN and Battafarano DF: Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 40:233–240. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Brănişteanu DE, Pintilie A, Andreş LE, Dimitriu A, Oanţă A, Stoleriu G and Brănişteanu DC: Ethiopatogenic hypotheses in lichen planus. Rev Med Chir Soc Med Nat Iasi. 120:770–776. 2016.PubMed/NCBI | |
|
Brănişteanu DE, Brănişteanu DC, Stoleriu G, Ferariu D, Voicu CM, Stoica LE, Căruntu C, Boda D, Filip-Ciubotaru FM, Dimitriu A and Radu CD: Histopathological and clinical traps in lichen sclerosus: A case report. Rom J Morphol Embryol. 57 (Suppl 2):S817–S823. 2016.PubMed/NCBI | |
|
Shaker MS, Wallace DV, Golden DBK, Oppenheimer J, Bernstein JA, Campbell RL, Dinakar C, Ellis A, Greenhawt M, Khan DA, et al: Anaphylaxis-a 2020 practice parameter update, systematic review, and grading of recommendations, assessment, development and evaluation (GRADE) analysis. J Allergy Clin Immunol. 145:1082–1123. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Murphy BA, Satinover SM, Hosen J, Mauro D, et al: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 358:1109–1117. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Torres MJ, Chaves P, Doña I, Blanca-López N, Canto G, Mayorga C and Blanca M: T-cell involvement in delayed-type hypersensitivity reactions to infliximab. J Allergy Clin Immunol. 128:1365–1367.e1. 2011.PubMed/NCBI View Article : Google Scholar | |
|
de Las Vecillas Sánchez L, Alenazy LA, Garcia-Neuer M and Castells MC: Drug hypersensitivity and desensitizations: Mechanisms and new approaches. Int J Mol Sci. 18(1316)2017.PubMed/NCBI View Article : Google Scholar | |
|
Cortellini G, Mascella F, Simoncelli M, Lippolis D, Focherini MC, Cortellini F, Cherubini C, Gavioli B and Ballardini G: Effective desensitization to tocilizumab in delayed hypersensitivity reaction. Pharmacology. 102:114–116. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Quercia O, Emiliani F, Foschi FG and Stefanini GF: Adalimumab desensitization after anaphylactic reaction. Ann Allergy Asthma Immunol. 106:547–548. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Pruzansky JJ and Patterson R: Desensitization of human basophils with suboptimal concentrations of agonist. Evidence for reversible and irreversible desensitization. Immunology. 65:443–447. 1988.PubMed/NCBI | |
|
MacGlashan D Jr and Lichtenstein LM: Basic characteristics of human lung mast cell desensitization. J Immunol. 139:501–505. 1987.PubMed/NCBI | |
|
del Carmen Sancho M, Breslow R, Sloane D and Castells M: Desensitization for hypersensitivity reactions to medications. Chem Immunol Allergy. 97:217–233. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Aydogan M, Yologlu N, Gacar G, Uyan ZS, Eser I and Karaoz E: Successful rapid rituximab desensitization in an adolescent patient with nephrotic syndrome: Increase in number of Treg cells after desensitization. J Allergy Clin Immunol. 132:478–480. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Macglashan D and Miura K: Loss of syk kinase during IgE-mediated stimulation of human basophils. J Allergy Clin Immunol. 114:1317–1324. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Görgülü B, Toprak SK and Bavbek S: Successful desensitization to brentuximab after anaphylactic shock. J Investig Allergol Clin Immunol. 28:352–354. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Pérez-Rodríguez E, Martínez-Tadeo JA, Pérez-Rodríguez N, Hernández-Santana G, Callero-Viera A, Rodríguez-Plata E and García-Robaina JC: Outcome of 490 desensitizations to chemotherapy drugs with a rapid one-solution protocol. J Allergy Clin Immunol Pract. 6:1621–1627.e6. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Erdogan T, Yasar Bilge NS and Kasifoglu T: Successful slow tocilizumab desensitization in a patient with adult onset Still disease. Biologicals. 55:17–18. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Bavbek S, Kendirlinan R, Çerçi P, Altıner S, Soyyiğit Ş, Çelebi Sözener Z, Aydın Ö and Gümüşburun R: rapid drug desensitization with biologics: A single-center experience with four biologics. Int Arch Allergy Immunol. 171:227–233. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Lieberman P, Nicklas RA, Randolph C, Oppenheimer J, Bernstein D, Bernstein J, Ellis A, Golden DB, Greenberger P, Kemp S, et al: Anaphylaxis-a practice parameter update 2015. Ann Allergy Asthma Immunol. 115:341–384. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Madrigal-Burgaleta R, Vazquez-Revuelta P, Marti-Garrido J, Lleonart R, Ali FR and Alvarez-Cuesta E: Importance of diagnostics prior to desensitization in new drug hypersensitivity: Chemotherapeutics and biologicals. Curr Treat Options Allergy. 7:1–13. 2020. | |
|
Creţu A, Dimitriu A, Brănişteanu D and Branişteanu DE: Erythema multiforme-etiopathogenic, clinical and therapeutic aspects. Rev Med Chir Soc Med Nat Iasi. 119:55–61. 2015.PubMed/NCBI | |
|
Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, et al: Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 122:574–580. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Herrero T, Tornero P, Infante S, Fuentes V, Sánchez MN, De Barrio M and Baeza ML: Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investig Allergol Clin Immunol. 16:327–330. 2006.PubMed/NCBI | |
|
Breslow RG, Caiado J and Castells MC: Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol. 102:155–160. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Ojaimi S, Harnett PR and Fulcher D: Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels. J Allergy Clin Immunol Pract. 2:105–106. 2014.PubMed/NCBI View Article : Google Scholar |
